Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$25487.0.

  • 60 Degrees Pharmaceuticals' Cash from Investing Activities rose 9854.08% to -$25487.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 18309.11%. This contributed to the annual value of -$1.9 million for FY2024, which is 153012.05% down from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' Cash from Investing Activities stood at -$25487.0, which was up 9854.08% from -$51684.0 recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $1.7 million during Q1 2025, with a 5-year trough of -$1.7 million in Q3 2024.
  • Moreover, its 4-year median value for Cash from Investing Activities was -$25487.0 (2025), whereas its average is -$33606.2.
  • In the last 5 years, 60 Degrees Pharmaceuticals' Cash from Investing Activities plummeted by 615879.89% in 2024 and then soared by 1744785.0% in 2025.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Cash from Investing Activities stood at -$58645.0 in 2022, then decreased by 13.5% to -$66562.0 in 2023, then soared by 96.85% to -$2098.0 in 2024, then crashed by 1114.82% to -$25487.0 in 2025.
  • Its Cash from Investing Activities was -$25487.0 in Q3 2025, compared to -$51684.0 in Q2 2025 and $1.7 million in Q1 2025.